Last reviewed · How we verify
XC8
XC8 is a small molecule that targets the SGLT2 receptor.
XC8 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | XC8 |
|---|---|
| Also known as | Histamine glutarimide |
| Sponsor | Valenta Pharm JSC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, XC8 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections (PHASE3)
- Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers (NA)
- Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection (PHASE3)
- Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets (PHASE1)
- Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection (PHASE2)
- XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma (PHASE2)
- Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children (PHASE4)
- XC8 in the Treatment of Patients With Bronchial Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XC8 CI brief — competitive landscape report
- XC8 updates RSS · CI watch RSS
- Valenta Pharm JSC portfolio CI